[Mental health. Photo Credit: Pixabay]

On January 13th, researchers revealed that those with the most severe, treatment-resistant depression experienced long-lasting alleviation with an implanted device that stimulates the vagus nerve. 

Around one in five patients were symptom-free after two years, with many patients reporting sustained improvements for years.

In the United States, one in five people will suffer from serious depression at some point in their lives. 

Many people improve after a few treatments, however up to one-third of patients do not get enough relief from psychotherapy or typical antidepressants. 

Treatment-resistant depression is a disorder that can last for years or even decades. 

For  the most severe cases of the sickness, the new study now indicates that a small implanted device may provide significant and long-lasting benefits.

To evaluate this approach, researchers at Washington University School of Medicine in St. Louis (Washu) oversaw a sizable, multicenter clinical trial. 

Researchers found that a vagus nerve stimulation device was associated with long-lasting benefits in everyday functioning, overall quality of life, and depressive symptoms. 

The majority of patients who showed improvement within a year maintained such improvements for a minimum of two years.

The study's subjects had been dealing with depression for an average of 29 years and had tried roughly 13 unsuccessful therapies. 

These emphasized the difficulty of treating their disease by offering intensive treatments like transcranial magnetic stimulation and electroconvulsive therapy.

The International Journal of Neuropsychopharmacology recently published the latest findings from the ongoing RECOVER experiment.

The sample in this trial, according to the researchers at the WashU Medicine Treatment Resistant Mood Disorders Center, is the sickest treatment-resistant depressed patient sample ever examined in a clinical trial. 

Since these patients frequently have no other options, it is necessary to identify effective treatments.

Even a partial response to treatment for this type of chronic, incapacitating illness can change a person's life, and vagus nerve stimulation is showing promising long-lasting benefits.

The purpose of the RECOVER trial was to determine whether treatment-resistant depression patients' outcomes could be enhanced by including vagus nerve stimulation (VNS) into their regular therapy. 

A gadget is surgically inserted beneath the skin in the chest as part of the therapy. 

The left vagus nerve, a crucial communication channel between the brain and numerous internal organs, receives precisely regulated electrical signals from the device.

The RECOVER trial was sponsored and funded by LivaNova USA, Inc., the manufacturer of the VNS Therapy System. 

Across 84 sites in the US, about 500 patients were enrolled, and approximately 75% of participants experienced depression to such an extent that they were unable to work. 

To enable comparison, only half of the patients had their implanted device enabled during the first year after receiving it. 

Researchers monitored changes in daily functioning, quality of life, and the degree of depression in both groups. 

People with severe treatment-resistant depression were the subjects of the study, which gathered long-term data on their mood, everyday functioning, and quality of life.

A primary goal of the research is to help the U.S. Centers for Medicare and Medicaid Services (CMS) make decisions about whether to increase coverage for the therapy. 

Since cost has been a significant barrier, approval might make the treatment accessible to many more individuals because many private insurers follow CMS's rulings.